• OUR STATEMENT ON COVID-19
    Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals, Inc.Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals, Inc.
    • About Us
    • Pipeline
    • Therapeutic focus
    • Contact us
    • Investors
    Open

    Press Releases

    Investors

    Investors

    • Overview
    • News & Events
      • Overview
      • Press Releases
      • IR Calendar
      • Videos
      • Email Alerts
    • Company Info
      • Overview
      • Management Team
      • Presentations
      • Contacts
      • FAQ
    • Financial Info
      • Overview
      • Financial Results
      • Income Statement
      • Balance Sheet
      • Cash Flow
    • Stock Data
      • Quote
      • Charts
      • Historical Data
      • Analyst Coverage
    • SEC Filings
      • Overview
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Governance
      • Overview
      • Board of Directors
      • Board Committees
      • Governance Documents
      • Board Diversity Matrix
    • News & Events

    • Overview
    • Press Releases
    • IR Calendar
    • Videos
    • Email Alerts
    Jul 05, 2022 6:00am EDT

    Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

    Jun 23, 2022 4:00pm EDT

    Anebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022

    May 24, 2022 4:00pm EDT

    Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer

    May 11, 2022 9:00am EDT

    Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates

    Apr 01, 2022 7:00am EDT

    Anebulo Pharmaceuticals Doses More Than Half of the Subjects in Part A of a Phase 2 Clinical Trial and Provides Guidance on IND Submission

    Feb 11, 2022 8:00am EST

    Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2022 Financial Results and Recent Updates

    Jan 06, 2022 7:00am EST

    Anebulo Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference

    Jan 06, 2022 7:00am EST

    Anebulo Pharmaceuticals Appoints Scott L. Anderson as Head of Investor Relations and Public Relations

    Jan 04, 2022 7:00am EST

    Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and Director

    Jan 03, 2022 7:00am EST

    Anebulo Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication

    • arrow_back
    • 1
    • 2
    • 3
    • arrow_forward
    rss_feed News RSS
    • Email Alerts
    • Contacts
    • RSS News Feed

    Contact

    Anebulo Pharmaceuticals
    1415 Ranch Road 620 South
    Austin, TX 78734
    Phone: 512-598-0931
    Email: info@anebulo.com

    About

    Our Mission
    Management Team
    Board of Directors

    Pipeline

    • ANEB-001
    Anebulo Pharmaceuticals, Inc.
    Facebook Twitter Instagram Reddit
    Back to top

    ©2023 Anebulo Pharmaceuticals. All Rights Reserved.

    Privacy Policy | Terms of Use